Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Merck & Co. (NYSE: MRK) | Delayed: 145.45 -0.15 (0.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.60 | 52 Week High | $65.46 | |||
| Open | $145.75 | 52 Week Low | $47.97 | |||
| Day High | $146.36 | P/E | 98.95 | |||
| Day Low | $144.64 | EPS | $1.47 | |||
| Volume | 6,626,935 | |||||
